<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549743</url>
  </required_header>
  <id_info>
    <org_study_id>HL-CER-101</org_study_id>
    <nct_id>NCT01549743</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetic Interaction Between Celecoxib and Rebamipide</brief_title>
  <official_title>Clinical Trial to Assess the Pharmacokinetic Interaction Between Celecoxib and Rebamipide in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This clinical trial aims to assess the pharmacokinetic interaction between celecoxib and&#xD;
      rebamipide in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 9, 2012</start_date>
  <completion_date type="Actual">June 13, 2012</completion_date>
  <primary_completion_date type="Actual">June 13, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax,ss, Cmin,ss, Tmax,ss, Cav,ss, AUCÏ„, DOF(= (Cmax-Cmin)/Cav), Swing</measure>
    <time_frame>Day1(0hr), Day2 (0hr), Day3 (0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48hr)</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rebamipide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib plus Rebamipide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Celecoxib 200mg will be administered orally twice a day for 3 days</description>
    <arm_group_label>Celecoxib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebamipide</intervention_name>
    <description>Rebamipide 100mg will be administered orally three times a day for 3 days</description>
    <arm_group_label>Rebamipide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib plus Rebamipide</intervention_name>
    <description>Celecoxib plus Rebamipide same way as &quot;arm: celecoxib&quot; and &quot;arm: rebamipide&quot;</description>
    <arm_group_label>Celecoxib plus Rebamipide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight ae least 50kg and BMI(body mass index) within the range of 18 to 27kg/m2&#xD;
&#xD;
          -  Agreement with written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with symptoms of acute disease within 28days prior to study medication dosing&#xD;
&#xD;
          -  Subject with known for history which affect on the absorption, distribution,&#xD;
             metabolism, excretion of drug&#xD;
&#xD;
          -  Subject with clinically significant active cardiovascular, respiratory, renal,&#xD;
             endocrine, hematologic, gastrointestinal, neurologic, autoimmunologic disease or&#xD;
             malignant tumor&#xD;
&#xD;
          -  Subject with unsuitable clinical test through the medical checkup(medical history,&#xD;
             physical examination, ECG, laboratory test) within 28days prior to study medication&#xD;
             dosing&#xD;
&#xD;
          -  Subject with any of the following findings; i. AST(sGOT) or ALT(sGPT) &gt; 1.5 fold&#xD;
             normal value or ii. Total bilirubin &gt; 1.5 fold normal value&#xD;
&#xD;
          -  Subject with clinically significant allergic disease (except for mild allergic&#xD;
             rhinitis, mild allergic dermatitis seems to be not need for medication)&#xD;
&#xD;
          -  Subject with known for hypersensitivity reaction to celecoxib, rebamipide,&#xD;
             sulphonamide analog&#xD;
&#xD;
          -  Subject with asthma, acute rhinitis, nasal polyp, angioedema, urticaria, allergic&#xD;
             reaction to aspirin or any other NSAIDs(including COX-2 inhibitors)&#xD;
&#xD;
          -  Subject with hereditary disorders such as galactose intolerance, Lapp lactase&#xD;
             deficiency or glucose-galactose malabsorption&#xD;
&#xD;
          -  Use of any prescription medication within 14 days prior to study medication dosing&#xD;
&#xD;
          -  Use of any medication(Over-the-counter medication, oriental medication, vitamin)&#xD;
             within 7 days prior to study medication dosing&#xD;
&#xD;
          -  Subject who has been taken meal which affect on the absorption, distribution,&#xD;
             metabolism, excretion of drug&#xD;
&#xD;
          -  Subject who is not able to taking the institutional standard meal&#xD;
&#xD;
          -  Whole blood donation within 60days, component blood donation within 20days or&#xD;
             receiving blood transfusion within 30days prior to study medication dosing&#xD;
&#xD;
          -  Participation in any clinical investigation within 60days prior to study medication&#xD;
             dosing&#xD;
&#xD;
          -  Continued excessive use of caffeine (caffeine &gt; five cups/day),&#xD;
             alcohol(alcohol&gt;30g/day) and severe heavy smoker(cigarette &gt; 10 cigarettes per day)&#xD;
&#xD;
          -  An impossible one who participate in clinical trial by investigator's decision&#xD;
             including for reason of laboratory test result&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Young Park, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Korea Univertisy Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <last_update_submitted>August 16, 2018</last_update_submitted>
  <last_update_submitted_qc>August 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Rebamipide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

